Boulder, CO (PRWEB) September 05, 2012
Sophono, Inc., a medical device manufacturer specializing in implantable, bone conduction hearing devices, announced today that the company will introduce its second-generation hearing device at the American Academy of Otolaryngology Annual Meeting & Expo in Washington, D.C., Sept. 9-12, exhibiting at Booth No. 1146.
The new Alpha 2 device leverages all the features and benefits of the Sophono Alpha 1 with a next-generation sound processor as well as other advanced features. The Sophono Alpha is the only abutment-free, implantable, bone-anchored hearing device available today. Working by implanting magnets to attach an external audio processor to a patient’s skull, the non-percutaneous Alpha eliminates problematic abutment issues inherent in other devices.
The Alpha device is designed for individuals suffering from severe to profound hearing loss or impairment, specifically those with conductive hearing loss (outer or middle ear), mixed hearing loss (both middle and inner ear), and single-ear deafness. The Alpha 2 can help children with aural artesia and microtia, individuals with chronic inflammation or infection of the ear canal, and others unable to wear traditional hearing aids.
New with Alpha 2
The new Alpha 2 device adds several key features, says Jim Kasic, president and CEO of Sophono. “The Sophono Alpha already is the simplest, safest, most hygienic device available to treat conductive hearing loss and single-ear deafness conditions,” he explains. “Now, with the Alpha 2, the device is not only abutment-free, but even more attractive to physicians, audiologists and patients.” The Alpha 2 has the following advanced features:
Advancement in treatment
With the Sophono Alpha, the surgeon uses magnets to attach an audio processor to a patient’s skull. That external processor picks up sounds, digitally amplifies them, and converts them into vibrations that travel through the skin and skull to the cochlea in the ear. The wearer then can hear the sounds.
The Sophono Alpha represents a significant improvement in treating applicable conditions, according to Kasic. Other devices incorporate a skin-penetrating abutment that protrudes permanently through the scalp. Use of these devices results in high infection and complication rates, which leads to low adoption and user rates. The Sophono Alpha eliminates the problematic abutment issue with a safe, hygienic, cosmetically appealing solution.
The simple, single-stage surgical procedure to implant the Alpha device features a low complication rate and small incision that heals quickly and completely. The consistent, predictable procedure results in activation times of approximately 30 days – vs. several months for other devices. The Sophono Alpha is FDA-cleared and reimbursable by most major insurance companies.
Sophono, Inc., is a medical device manufacturer specializing in implantable, bone conduction hearing devices. The company’s products are designed for individuals suffering from severe to profound hearing loss or impairment. The Sophono Alpha is the only abutment-free, implantable, bone-anchored hearing device. Treating those with conductive hearing loss, mixed hearing loss, and single-ear deafness, the FDA-cleared product Alpha eliminates the problematic abutment of devices by using magnets to affix external sound processors.
Sophono corporate headquarters and manufacturing operations reside in Boulder, Colo. The company maintains an office in Germany, and sells through distributors in more than 20 countries.